COVID-19

COVID-19

With COVID-19 having surpassed cancer in terms of being the second highest killer in the USA this year, the medical and pharmaceutical research companies are striving to find effective vaccines and curative treatments.

While many of the candidates that were expected to succeed have failed, there have been some encouraging developments, such as with Remdesivir. Nonetheless, the road ahead is long and daunting, and it will take creative synergies between the medical, pharmaceutical and imaging teams to come up with effective and expedient solutions for COVID-19.

SARS-Cov2 is an RNA virus from the coronaviridae family, and has shown high virulence and transmissibility, and that combined with the lack of a specific vaccine or effective treatment, has led to COVID-19 being the pandemic of the century.

The first need of the hour is to fast-track the trials for vaccines that produce lasting immunity, which entails developing candidates and performing trials on humans and monitoring their titers via serology. While the ongoing trials are employing essentially the same trial design, there is a room to creatively utilize novel tools that can provide new targets for vaccine development and expedite the process through more effective trial designs.

Imaging can play a role here. We can extract useful imaging biomarkers from standard imaging modalities to play an important role in COVID-19 trials. Furthermore, thanks to advancements in immuno-oncology, there are new imaging strategies that monitor changes in the cellular as well as humoral immune changes in response to a pathogen or a cancer cell.

Novel imaging strategies (such as T-cell PET, immunoPET or ferumoxytol imaging) can help us study the viral attack and the ensuing immune response against it, and as a result, allow us to find optimal vaccine candidates and help monitor the immune response they elicit.

Similarly, therapeutic trials for COVID-19 have also borrowed strategies from immuno-oncology. There are novel and repurposed immunotherapeutic approaches that are being targeted against COVID-19, including monoclonal antibodies against pro-inflammatory cytokines or specific SARS-Cov2 antigens. Previously mentioned immune system imaging strategies can be leveraged here as well – not only to find better drug candidates, but to assess their target activity, distribution and therapy response as well.

At IAG, we are addressing the needs of these trials in the following ways:

  • Providing imaging expertise in developing structural (CT/CXR) biomarkers to serve as primary/secondary endpoints for COVID-19 trials.
  • Using radiomics as well as other artificial intelligence-based scoring systems that help to stratify and prognosticate patients for clinical and drug development purposes.
  • Providing imaging expertise in advanced imaging approaches (such as T-cell PET, immunoPET) to deliver biomarkers that serve as exploratory endpoints or surrogate markers for COVID-19 trials.
  • Providing state-of-the-art clinical trials design and strategic solutions to meet the unique set of challenges encountered in COVID-19 trials.

Whether it is scientific creativity and robustness or excellence in business practices, IAG is committed to being a leading imaging CRO that is nuanced in its COVID-19 related services to the biopharma community.

READ NEXT CASE STUDY >
Experience: Scoring Systems
  • Semi-Quantitative Scoring
  • Quantitative Lung Fibrosis Score
Experience: Imaging
  • Chest X-Ray
  • CT
  • ImmunoPET
  • T-Cell PET
  • Ferumoxytol Imaging
Publications

Since 2007, over 2000 articles were published to cover scientific discoveries, technology break-throughs and special cases. We list here some critically important papers and abstracts.

Testimonials

Combining our technologies and business advisory services with promising life science companies has yielded spectacular results over the past five years. As a trusted partner to many biotech and pharma companies, IAG’s team is proud to share your words and quotes.

IDIOPATHIC PULMONARY FIBROSIS (IPF)

IDIOPATHIC PULMONARY FIBROSIS

Interstitial lung disease (ILD) refers to a group of lung diseases affecting the interstitium. It is associated with wide spread inflammation and fibrosis of the alveolar walls, compromising alveoli function and gas exchange. Idiopathic Pulmonary Fibrosis (IPF) is one of the most major types of ILD.

IPF is believed to be associated with aberrant wound healing and the excessive deposition of collagen in the pulmonary interstitium, with minimal associated inflammation. The 5-year survival rate of individuals affected with IPF is roughly 20%, aetiology is idiopathic with familial IPF accounting for just 5% of cases.

Standard treatments for IPF include anti-fibrotic and anti-inflammatory drugs, with the goals of treatment being alleviation of some of the symptoms, reducing speed of propagation and preventing acute exacerbations.

IAG’s team experience in clinical trials focuses on the patient stratification and finding the optimal imaging based endpoints to assess the treatment induced changes.

At patient stratification, we focus on assisting physicians with distinguishing I{F patients from those with COPD and asthma. Usually it involves collaboration within a multi-disciplinary team of a pulmonologist, radiologist and pathologist.

IAG’s radiology team has extensive experience with using High Resolution Computed Tomography (HRCT) to characterize and classification patients with lung diseases. This modality can be utilized without the use of contrast agents and can image slices up to a resolution of 1-2mm revealing detail of the entire ling parenchyma. The HRCT imaging findings obtained usually complement the histologic findings on post-mortem/biopsy.

To assess the impact of a novel therapy, IAG’s team bring knowledge of qualitative and quantitative systems to assess:

  • Pure ground glass opacity,
  • Lung fibrosis,
  • Honeycombing,
  • Emphysema.

IAG’s team are activity contributing to the research in lung diseases and led development of novel methodologies and scoring using advanced imaging, including MRI and molecular imaging

Reach out to our expert team, as you are designing and planning your trial.

About IAG, Image Analysis Group

IAG, Image Analysis Group is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development, and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed.

Contact our expert team: imaging.experts @ ia-grp.com

READ NEXT CASE STUDY >
Experience: Scoring Systems
  • Semi-Quantitative Scoring
  • Quantitative Lung Fibrosis Score
Experience: Imaging
  • High Resolution Computed Tomography (HRCT)
  • MRI
  • PET
Publications

Since 2007, over 2000 articles were published to cover scientific discoveries, technology break-throughs and special cases. We list here some critically important papers and abstracts.

Testimonials

Combining our technologies and business advisory services with promising life science companies has yielded spectacular results over the past five years. As a trusted partner to many biotech and pharma companies, IAG’s team is proud to share your words and quotes.